Cargando…
Efficacy and safety of ipragliflozin as add‐on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a multi‐centre, randomized, placebo‐controlled, double‐blind study
AIMS: To examine the efficacy and safety of add‐on ipragliflozin in Japanese patients with type 2 diabetes in the early stage of insulin therapy. METHODS: Patients treated with insulin (bolus component <30% of total daily dose) with/without a dipeptidyl peptidase‐4 (DPP‐4) inhibitor were randomiz...
Autores principales: | Ishihara, Hisamitsu, Yamaguchi, Susumu, Nakao, Ikko, Okitsu, Akira, Asahina, Seitaro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5484364/ https://www.ncbi.nlm.nih.gov/pubmed/27436788 http://dx.doi.org/10.1111/dom.12745 |
Ejemplares similares
-
Ipragliflozin Add-on Therapy to a GLP-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes (AGATE): A 52-Week Open-Label Study
por: Ishihara, Hisamitsu, et al.
Publicado: (2018) -
Open-Label Study to Assess the Efficacy of Ipragliflozin for Reducing Insulin Dose in Patients with Type 2 Diabetes Mellitus Receiving Insulin Therapy
por: Ishihara, Hisamitsu, et al.
Publicado: (2019) -
Efficacy and safety of ipragliflozin add‐on therapy to insulin in Japanese patients with type 1 diabetes mellitus: A randomized, double‐blind, phase 3 trial
por: Kaku, Kohei, et al.
Publicado: (2019) -
Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study
por: Kashiwagi, A, et al.
Publicado: (2015) -
Randomized, placebo‐controlled, double‐blind glycemic control trial of novel sodium‐dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus
por: Kashiwagi, Atsunori, et al.
Publicado: (2013)